https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/UNH/codoxo-unitedhealth-fraud-strategies-nhcaa-2026 BiopharmaWatch en 2026-10-27T14:00:00.000Z Beyond Claims Data: Codoxo and UnitedHealth Group to Present Innovative Strategies for Uncovering Healthcare Fraud at NHCAA 2026 https://www.biopharmawatch.com/news/NNVC/nv-387-ebola-treatment-phase-ii-trial-update BiopharmaWatch en 2026-10-27T13:33:36.643Z As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides https://www.biopharmawatch.com/news/CHRS/coherus-participate-upcoming-investor-conferences-20261027 BiopharmaWatch en 2026-10-27T13:30:00.000Z Coherus to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ONCY/oncolytics-biotech-pelareorep-anal-cancer-data BiopharmaWatch en 2026-10-27T13:30:00.000Z Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers https://www.biopharmawatch.com/news/NXL/nexalin-15ma-difs-improves-sleep-quality-alzheimers BiopharmaWatch en 2026-10-27T13:00:00.000Z Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease https://www.biopharmawatch.com/news/PLUR/pluri-investor-conference-calls-updates BiopharmaWatch en 2026-10-27T13:00:00.000Z Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments https://www.biopharmawatch.com/news/XGN/exagen-announces-q3-financial-results-november-10-2026 BiopharmaWatch en 2026-10-27T13:00:00.000Z Exagen to Announce Third Quarter Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/ATYR/atyr-pharma-reverse-stock-split BiopharmaWatch en 2026-10-27T13:00:00.000Z aTyr Pharma Announces One-for-40 Reverse Stock Split https://www.biopharmawatch.com/news/VNRX/volitionrx-missionpharma-lateral-flow-technology-netosis BiopharmaWatch en 2026-10-27T12:47:00.000Z VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-micvo-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-10-27T12:45:00.000Z Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics https://www.biopharmawatch.com/news/ICCM/icecure-first-cryoablation-treatment-choicestudy BiopharmaWatch en 2026-10-27T12:33:00.000Z IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation https://www.biopharmawatch.com/news/DCTH/delcath-systems-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-27T12:30:00.000Z Delcath Systems to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AMGN/nord-amgen-learning-collaborative-rare-disease BiopharmaWatch en 2026-10-27T12:30:00.000Z NORD and Amgen Launch Learning Collaborative to Improve Rare Disease Diagnosis and Care https://www.biopharmawatch.com/news/MBOT/microbot-medical-first-obl-customer-liberty-system BiopharmaWatch en 2026-10-27T12:30:00.000Z Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System https://www.biopharmawatch.com/news/ONCO/onconetix-acquisition-realbotix-echo-robot-launch BiopharmaWatch en 2026-10-27T12:30:00.000Z Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement https://www.biopharmawatch.com/news/NXGL/nexgel-regains-compliance-nasdaq-listing-requirement BiopharmaWatch en 2026-10-27T12:30:00.000Z NEXGEL Regains Compliance with Nasdaq Listing Requirement https://www.biopharmawatch.com/news/CMND/clearmind-completes-patient-recruitment-aud-trial BiopharmaWatch en 2026-10-27T12:22:00.000Z Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial https://www.biopharmawatch.com/news/VNRX/volitionrx-announces-partial-prepayment-convertible-note BiopharmaWatch en 2026-10-27T12:17:00.000Z VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash https://www.biopharmawatch.com/news/PLRZ/polyrizon-completes-enrollment-nasarix-allergy-blocker BiopharmaWatch en 2026-10-27T12:16:00.000Z Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesiosis-study-results BiopharmaWatch en 2026-10-27T12:06:00.000Z 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients https://www.biopharmawatch.com/news/BFLY/butterfly-network-presents-ubs-healthcare-conference-2026 BiopharmaWatch en 2026-10-27T12:05:00.000Z Butterfly Network to Present at UBS Global Healthcare Conference on November 10, 2026 https://www.biopharmawatch.com/news/HLF/herbalife-renews-commitment-red-cross-blood-saves-lives BiopharmaWatch en 2026-10-27T12:05:00.000Z Herbalife renews $1 million in-kind commitment to American Red Cross Blood Saves Lives program https://www.biopharmawatch.com/news/BLLN/billiontoone-participate-investor-conferences BiopharmaWatch en 2026-10-27T12:05:00.000Z BillionToOne to Participate in Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/CADL/candel-therapeutics-november-investor-conferences BiopharmaWatch en 2026-10-27T12:05:00.000Z Candel Therapeutics to Present at November Investor Conferences https://www.biopharmawatch.com/news/VYGR/voyager-gene-therapy-vy1706-anti-tau-antibody-vy7523-ctad-2026 BiopharmaWatch en 2026-10-27T12:01:00.000Z Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026 https://www.biopharmawatch.com/news/ABBV/abbvie-bla-etentamig-multiple-myeloma BiopharmaWatch en 2026-10-27T12:00:00.000Z AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma https://www.biopharmawatch.com/news/OGN/entera-appoints-dr-arjona-ferreira-board BiopharmaWatch en 2026-10-27T12:00:00.000Z Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-phase-2a-cadisegliatin-study BiopharmaWatch en 2026-10-27T12:00:00.000Z vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems https://www.biopharmawatch.com/news/SYK/stryker-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-10-27T12:00:00.000Z Stryker to participate in the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/ENLV/enlivex-delisting-notice-nasdaq-appeal BiopharmaWatch en 2026-10-27T12:00:00.000Z Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal https://www.biopharmawatch.com/news/ALT/altimmune-appoints-greenleaf-howarth-board-directors BiopharmaWatch en 2026-10-27T12:00:00.000Z Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q3-2026 BiopharmaWatch en 2026-10-27T12:00:00.000Z Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results https://www.biopharmawatch.com/news/MDGL/madrigal-presents-abstracts-aasld-liver-meeting-2026 BiopharmaWatch en 2026-10-27T12:00:00.000Z Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-esmo-2026-cld-401-data BiopharmaWatch en 2026-10-27T12:00:00.000Z Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-pricing-public-offering BiopharmaWatch en 2026-10-27T12:00:00.000Z Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-cta-approval-phase-1-2-trial-cmp-002 BiopharmaWatch en 2026-10-27T12:00:00.000Z CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union https://www.biopharmawatch.com/news/OPK/opko-biologics-phase-1-2a-trial-opk-8801001 BiopharmaWatch en 2026-10-27T12:00:00.000Z OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-10-27T12:00:00.000Z Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 https://www.biopharmawatch.com/news/NTRA/natera-esmo-congress-2026-bladder-cancer BiopharmaWatch en 2026-10-27T11:45:00.000Z Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer https://www.biopharmawatch.com/news/CODX/cosara-diagnostics-tuberculosis-test-launch-india BiopharmaWatch en 2026-10-27T11:45:00.000Z Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-bci-growth-strategy BiopharmaWatch en 2026-10-27T11:45:00.000Z Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform https://www.biopharmawatch.com/news/ZURA/zura-bio-third-quarter-2026-results BiopharmaWatch en 2026-10-27T11:30:00.000Z Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/NGNE/neurogene-ngn-401-data-esgct-congress BiopharmaWatch en 2026-10-27T11:30:00.000Z Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome https://www.biopharmawatch.com/news/JNJ/johnson-johnson-enterprise-business-review-2026 BiopharmaWatch en 2026-10-27T11:30:00.000Z Johnson & Johnson to Host Enterprise Business Review https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-27T11:30:00.000Z Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution https://www.biopharmawatch.com/news/IFRX/inflarx-announces-november-investor-events BiopharmaWatch en 2026-10-27T11:30:00.000Z InflaRx Announces November Investor Events https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-discontinues-allonk-development BiopharmaWatch en 2026-10-27T11:30:00.000Z Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK® https://www.biopharmawatch.com/news/MDCX/medicus-pharma-presents-biofuture-global-biotech-summit BiopharmaWatch en 2026-10-27T11:30:00.000Z Medicus Pharma to Present at BioFuture and Global Biotechnology Summit https://www.biopharmawatch.com/news/CNSY/cerenome-interim-update-respect-lm-trial BiopharmaWatch en 2026-10-27T11:30:00.000Z Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q3-2026-update BiopharmaWatch en 2026-10-27T11:30:00.000Z Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q3-2026-earnings-call BiopharmaWatch en 2026-10-27T11:30:00.000Z Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-27T11:30:00.000Z Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-case-study-iopofosine BiopharmaWatch en 2026-10-27T11:15:00.000Z Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-beam-301-phase-1-2-trial-data BiopharmaWatch en 2026-10-27T11:00:35.000Z Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress https://www.biopharmawatch.com/news/MSLE/satellos-scientific-advisory-board-regeneration-aging BiopharmaWatch en 2026-10-27T11:00:00.000Z Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-investment-conferences-november-2026 BiopharmaWatch en 2026-10-27T11:00:00.000Z Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026 https://www.biopharmawatch.com/news/HCA/hca-healthcare-reports-q3-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z HCA Healthcare Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/FTH/faeth-appoints-adam-schayowitz-board-directors BiopharmaWatch en 2026-10-27T11:00:00.000Z Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors https://www.biopharmawatch.com/news/IQV/iqvia-reports-third-quarter-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z IQVIA Reports Third-Quarter 2026 Results https://www.biopharmawatch.com/news/STVN/aptar-pharma-stevanato-group-pre-filled-syringe BiopharmaWatch en 2026-10-27T11:00:00.000Z Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection https://www.biopharmawatch.com/news/STVN/stevanato-aptar-collaboration-prefilled-syringe-selection BiopharmaWatch en 2026-10-27T11:00:00.000Z Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection https://www.biopharmawatch.com/news/MASS/908-devices-third-quarter-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z 908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/RGEN/repligen-reports-q3-2026-results-and-guidance BiopharmaWatch en 2026-10-27T11:00:00.000Z Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://www.biopharmawatch.com/news/NRXS/neuraxis-third-quarter-2026-results-call BiopharmaWatch en 2026-10-27T11:00:00.000Z NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026 https://www.biopharmawatch.com/news/TNXP/tonix-phase-3-tonmya-fibromyalgia-data-iasp-2026 BiopharmaWatch en 2026-10-27T11:00:00.000Z Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/ARVN/arvinas-third-quarter-2026-financial-results-webcast BiopharmaWatch en 2026-10-27T11:00:00.000Z Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q3-2026-results-conference-call BiopharmaWatch en 2026-10-27T11:00:00.000Z Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q3-2026-results-update BiopharmaWatch en 2026-10-27T11:00:00.000Z Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/BVS/bioventus-q3-fiscal-year-2026-results BiopharmaWatch en 2026-10-27T11:00:00.000Z Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/ADAG/adagene-participate-guggenheim-healthcare-conference BiopharmaWatch en 2026-10-27T11:00:00.000Z Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/FTRE/fortrea-participate-jefferies-global-healthcare-conference BiopharmaWatch en 2026-10-27T11:00:00.000Z Fortrea to Participate in Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-velinotamig-clinical-trial BiopharmaWatch en 2026-10-27T11:00:00.000Z Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA https://www.biopharmawatch.com/news/SNDL/sndl-reports-q3-2026-results BiopharmaWatch en 2026-10-27T10:55:00.000Z SNDL Reports Third Quarter 2026 Financial and Operational Results https://www.biopharmawatch.com/news/VNDA/vanda-nereus-positive-results-study-3601 BiopharmaWatch en 2026-10-27T10:50:00.000Z Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting https://www.biopharmawatch.com/news/PFE/pfizer-elrexfio-phase-3-study-results BiopharmaWatch en 2026-10-27T10:45:00.000Z Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-50-million-offering BiopharmaWatch en 2026-10-27T10:43:00.000Z Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/INFU/infusystem-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-27T10:30:00.000Z InfuSystem to Report Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/CMPS/compass-pathways-q3-2026-financial-results-announcement BiopharmaWatch en 2026-10-27T10:30:00.000Z Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026 https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-doses-first-patient-corventis-trial BiopharmaWatch en 2026-10-27T10:30:00.000Z Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome https://www.biopharmawatch.com/news/IMRN/immuron-quarterly-sales-growth-october-2026 BiopharmaWatch en 2026-10-27T10:00:00.000Z Immuron continued quarterly sales growth https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q3-2026-financial-results BiopharmaWatch en 2026-10-27T10:00:00.000Z Nautilus Biotechnology Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-positive-phase-1b-results-ati-052 BiopharmaWatch en 2026-10-27T10:00:00.000Z Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma https://www.biopharmawatch.com/news/AVR/anteris-data-release-duravr-thv-tct-2026 BiopharmaWatch en 2026-10-27T10:00:00.000Z Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026 https://www.biopharmawatch.com/news/CLLS/cellectis-preclinical-data-apoc3-editing-esgct-2026 BiopharmaWatch en 2026-10-27T07:15:00.000Z Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 https://www.biopharmawatch.com/news/IPHA/innate-pharma-pacific-9-trial-timing-update BiopharmaWatch en 2026-10-27T06:00:00.000Z Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 https://www.biopharmawatch.com/news/PHAR/pharming-q3-2026-financial-results-revenue-growth BiopharmaWatch en 2026-10-27T06:00:00.000Z Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November https://www.biopharmawatch.com/news/NVS/novartis-q3-2026-sales-growth-guidance BiopharmaWatch en 2026-10-27T06:00:00.000Z Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q3-2026-results-call BiopharmaWatch en 2026-10-27T00:10:29.000Z Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/HCM/hutchmed-savolitinib-webcast-esmo-2026 BiopharmaWatch en 2026-10-27T00:00:00.000Z Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/ULS/ul-solutions-expands-testing-facility-vietnam BiopharmaWatch en 2026-10-26T22:00:00.000Z UL Solutions Opens Expanded Product Testing Facility in Vietnam https://www.biopharmawatch.com/news/AMGN/amgen-appoints-david-gibbs-board-directors BiopharmaWatch en 2026-10-26T21:52:00.000Z AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS https://www.biopharmawatch.com/news/NYXH/nyxoah-q3-2026-financial-results-release BiopharmaWatch en 2026-10-26T21:05:00.000Z Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/ONCO/onconetix-reverse-stock-split BiopharmaWatch en 2026-10-26T21:03:00.000Z Onconetix Announces Reverse Stock Split https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-ifetroban-nda BiopharmaWatch en 2026-10-26T20:40:00.000Z CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261026 BiopharmaWatch en 2026-10-26T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-26T20:30:00.000Z Travere Therapeutics to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-10-26T20:30:00.000Z Sarepta Therapeutics to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/EHC/encompass-health-expands-fort-bend-county-texas BiopharmaWatch en 2026-10-26T20:30:00.000Z Encompass Health expands in Fort Bend County, Texas, with second small-format hospital in Houston area https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-q3-2026-results-conference-call BiopharmaWatch en 2026-10-26T20:15:00.000Z Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-q3-2026-results-call BiopharmaWatch en 2026-10-26T20:15:00.000Z Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 https://www.biopharmawatch.com/news/SLBT/sl-science-holding-limited-first-half-2026-results BiopharmaWatch en 2026-10-26T20:15:00.000Z SL Science Holding Limited Reports First Half 2026 Financial Results https://www.biopharmawatch.com/news/LYCA/lycia-therapeutics-ipo-closing-october-2026 BiopharmaWatch en 2026-10-26T20:12:00.000Z Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/CLOV/clover-health-ubs-global-healthcare-conference-2026 BiopharmaWatch en 2026-10-26T20:05:29.000Z Clover Health to Participate in Upcoming UBS Global Healthcare Conference https://www.biopharmawatch.com/news/RXRX/recursion-webinar-updated-rec-4881-data-november-3 BiopharmaWatch en 2026-10-26T20:05:00.000Z Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 https://www.biopharmawatch.com/news/OABI/omniab-participate-investor-conferences-november BiopharmaWatch en 2026-10-26T20:05:00.000Z OmniAb to Participate in Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/OSUR/orasure-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-26T20:05:00.000Z OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-announces-new-employee-inducement-grants-20261026 BiopharmaWatch en 2026-10-26T20:01:00.000Z Definium Therapeutics Announces New Employee Inducement Grants https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-10-26T20:01:00.000Z Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026 https://www.biopharmawatch.com/news/RDNT/radnet-acquires-onrad BiopharmaWatch en 2026-10-26T20:01:00.000Z RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc. https://www.biopharmawatch.com/news/PFE/talzenna-xtandi-fda-approval-prostate-cancer BiopharmaWatch en 2026-10-26T17:41:00.000Z Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting https://www.biopharmawatch.com/news/PFE/pfizer-talzenna-xtandi-fda-approval-prostate-cancer BiopharmaWatch en 2026-10-26T17:41:00.000Z Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-growth-fiscal-q4-2026 BiopharmaWatch en 2026-10-26T17:00:00.000Z Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261026 BiopharmaWatch en 2026-10-26T15:57:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/MRK/keytruda-monotherapy-endometrial-cancer-trial-results BiopharmaWatch en 2026-10-26T15:35:00.000Z KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy https://www.biopharmawatch.com/news/MRK/sacituzumab-tirumotecan-trial-results-endometrial-cancer BiopharmaWatch en 2026-10-26T15:30:00.000Z Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer https://www.biopharmawatch.com/news/LLY/lilly-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-26T15:19:00.000Z Lilly declares fourth-quarter 2026 dividend https://www.biopharmawatch.com/news/ZBH/comeback-club-joint-replacement-launch BiopharmaWatch en 2026-10-26T14:21:00.000Z Arthritis Foundation and Founding Sponsor Zimmer Biomet Announce New Community Celebrating Life After Joint Replacement and Inspiring Others to Act on Severe Joint Pain https://www.biopharmawatch.com/news/INCY/incyte-gastrointestinal-cancer-esmo-2026 BiopharmaWatch en 2026-10-26T13:45:00.000Z Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 https://www.biopharmawatch.com/news/CHRS/coherus-oncology-third-quarter-2026-results BiopharmaWatch en 2026-10-26T13:30:00.000Z Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/HSTM/healthstream-host-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-26T13:25:00.000Z HealthStream to Host Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/AKBA/u-s-renal-care-presents-analysis-voice-trial-demonstrating-favorable BiopharmaWatch en 2026-10-26T13:20:00.000Z U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week https://www.biopharmawatch.com/news/AKBA/us-renal-care-voice-trial-vadadustat-safety-outcomes BiopharmaWatch en 2026-10-26T13:20:00.000Z U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week https://www.biopharmawatch.com/news/NTHI/neonc-expands-brain-cancer-trial-500-patients BiopharmaWatch en 2026-10-26T13:19:00.000Z NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries https://www.biopharmawatch.com/news/LGVN/longeveron-elpis-ii-phase-2b-results-hlhs BiopharmaWatch en 2026-10-26T13:15:00.000Z Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) https://www.biopharmawatch.com/news/BMRN/biomarin-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-26T13:00:00.000Z BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET https://www.biopharmawatch.com/news/ABT/abbott-launches-oncodetect-mrd-test-cancer-detection BiopharmaWatch en 2026-10-26T13:00:00.000Z Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment https://www.biopharmawatch.com/news/SGRY/healthspan-partners-acquire-surgery-partners BiopharmaWatch en 2026-10-26T13:00:00.000Z HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Platform https://www.biopharmawatch.com/news/ALGN/align-technology-commits-1-million-aao-foundation BiopharmaWatch en 2026-10-26T13:00:00.000Z Align Technology Commits Additional $1 Million to the American Association of Orthodontists Foundation to Support the Next Generation of Orthodontic Educators and Leaders https://www.biopharmawatch.com/news/STLN/starling-oncology-q3-2026-earnings-release BiopharmaWatch en 2026-10-26T13:00:00.000Z Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/ACB/aurora-cannabis-curaleaf-application-dismissed BiopharmaWatch en 2026-10-26T12:47:00.000Z Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program https://www.biopharmawatch.com/news/AZTR/azitra-ex-vivo-study-atr-cosf-results BiopharmaWatch en 2026-10-26T12:45:00.000Z Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin https://www.biopharmawatch.com/news/DARE/dare-bioscience-dare-idds-podd-2026 BiopharmaWatch en 2026-10-26T12:32:00.000Z Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly https://www.biopharmawatch.com/news/BEAT/heartbeam-fda-total-product-life-cycle-advisory-program BiopharmaWatch en 2026-10-26T12:31:00.000Z HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-ingrezza-tardive-dyskinesia-analysis BiopharmaWatch en 2026-10-26T12:30:00.000Z Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-completion-treatment-fifth-cohort-ovarian-cancer-car BiopharmaWatch en 2026-10-26T12:30:00.000Z Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial https://www.biopharmawatch.com/news/DCTH/delcath-systems-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-26T12:30:00.000Z Delcath Systems to Host Third Quarter 2026 Earnings Call https://www.biopharmawatch.com/news/SDGR/schrodinger-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261026 BiopharmaWatch en 2026-10-26T12:30:00.000Z Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NVCT/nuvectis-nxp200-phase-1b-study-results BiopharmaWatch en 2026-10-26T12:30:00.000Z Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas https://www.biopharmawatch.com/news/EQ/equillium-phase-1-trial-eq504-dosing BiopharmaWatch en 2026-10-26T12:30:00.000Z Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 https://www.biopharmawatch.com/news/SSII/ss-innovations-ss-mantra-telesurgery-october-2026 BiopharmaWatch en 2026-10-26T12:30:00.000Z SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-investor-conferences-nov-dec-2026 BiopharmaWatch en 2026-10-26T12:30:00.000Z Allogene Therapeutics Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-chemotherapy-resistant-cancer BiopharmaWatch en 2026-10-26T12:30:00.000Z Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability https://www.biopharmawatch.com/news/AVTR/avantor-appoints-new-cio BiopharmaWatch en 2026-10-26T12:05:00.000Z Avantor appoints new Chief Information Officer https://www.biopharmawatch.com/news/APVO/apvo-mipletamig-aml-stem-cell-transplant BiopharmaWatch en 2026-10-26T12:05:00.000Z Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q3-2026-financial-results-call BiopharmaWatch en 2026-10-26T12:01:00.000Z Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update https://www.biopharmawatch.com/news/HEPA/hepion-fda-feedback-gv104-fentanyl-cardiac-arrest BiopharmaWatch en 2026-10-26T12:01:00.000Z Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest https://www.biopharmawatch.com/news/ASPI/renergen-virginia-gas-project-stable-helium-production BiopharmaWatch en 2026-10-26T12:00:00.000Z ASP Isotopes Inc. Announces that Renergen Limited’s Virginia Gas Project has Achieved Stable Liquid Helium Production https://www.biopharmawatch.com/news/BSX/boston-scientific-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-26T12:00:00.000Z Boston Scientific to participate in Stifel's 2026 Healthcare Conference https://www.biopharmawatch.com/news/EVGN/evogene-participate-bio-europe-drug-discovery-chemistry BiopharmaWatch en 2026-10-26T12:00:00.000Z Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain https://www.biopharmawatch.com/news/VBIO/valion-bio-acquisition-interest-velocity-bioworks BiopharmaWatch en 2026-10-26T12:00:00.000Z Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-results-november-12 BiopharmaWatch en 2026-10-26T12:00:00.000Z Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/ATRC/atricure-participate-upcoming-investor-conferences BiopharmaWatch en 2026-10-26T12:00:00.000Z AtriCure to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/CORT/corcept-phase-2-bella-trial-results BiopharmaWatch en 2026-10-26T12:00:00.000Z Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer https://www.biopharmawatch.com/news/CVM/cel-sci-phase-3-multikine-data-world-congress BiopharmaWatch en 2026-10-26T12:00:00.000Z CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival https://www.biopharmawatch.com/news/MIRM/mirum-positive-results-progress-study-atebrioz BiopharmaWatch en 2026-10-26T12:00:00.000Z Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-ceo-appointment BiopharmaWatch en 2026-10-26T12:00:00.000Z Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-celia-economides-cfo-appointment BiopharmaWatch en 2026-10-26T12:00:00.000Z Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer https://www.biopharmawatch.com/news/SLDB/solid-biosciences-orphan-designation-sgt-212-falcon-trial BiopharmaWatch en 2026-10-26T12:00:00.000Z Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia https://www.biopharmawatch.com/news/OPTH/optimi-health-launches-australia-subsidiary BiopharmaWatch en 2026-10-26T12:00:00.000Z Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity https://www.biopharmawatch.com/news/BIVI/biovie-present-data-bezisterim-long-covid-recover-tlc BiopharmaWatch en 2026-10-26T12:00:00.000Z BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-leadership-immunology-pipeline BiopharmaWatch en 2026-10-26T12:00:00.000Z Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline https://www.biopharmawatch.com/news/ASND/transcon-pth-improves-kidney-function-hypoparathyroidism BiopharmaWatch en 2026-10-26T12:00:00.000Z TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years https://www.biopharmawatch.com/news/SYK/stryker-acquisition-zurimed-shoulder-offering BiopharmaWatch en 2026-10-26T12:00:00.000Z Stryker completes acquisition of ZuriMED to enhance its shoulder offering https://www.biopharmawatch.com/news/GTBP/gt-biopharma-sitc-2026-presentation BiopharmaWatch en 2026-10-26T12:00:00.000Z GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/HIND/vyome-dr-shiladitya-sengupta-harvard-promotion BiopharmaWatch en 2026-10-26T12:00:00.000Z Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art26-12-pain-treatment-iasp-2026 BiopharmaWatch en 2026-10-26T11:55:00.000Z Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-phase-1a-data-esmo-2026 BiopharmaWatch en 2026-10-26T11:31:00.000Z TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026 https://www.biopharmawatch.com/news/QUCY/quantum-cyber-invited-present-quantum-antenna-technology-quantumct-quantum-sensing BiopharmaWatch en 2026-10-26T11:30:00.000Z Quantum Cyber Invited to Present Quantum Antenna Technology at QuantumCT Quantum Sensing Convening https://www.biopharmawatch.com/news/QUCY/quantum-cyber-presents-antenna-technology-quantumct-convening BiopharmaWatch en 2026-10-26T11:30:00.000Z Quantum Cyber Invited to Present Quantum Antenna Technology at QuantumCT Quantum Sensing Convening https://www.biopharmawatch.com/news/FEED/envue-medical-shareholder-letter-october-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z ENvue Medical Issues Letter to Shareholders https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-ifx-2-0-keytruda-mcc-study-data BiopharmaWatch en 2026-10-26T11:30:00.000Z TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma https://www.biopharmawatch.com/news/BHVN/biohaven-oral-presentation-asn-kidney-week-2026-spotlights-bhv-1420 BiopharmaWatch en 2026-10-26T11:30:00.000Z Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1420-asn-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy https://www.biopharmawatch.com/news/CGC/canopy-growth-2026-annual-meeting-results BiopharmaWatch en 2026-10-26T11:30:00.000Z Canopy Growth Announces Results of 2026 Annual General and Special Meeting of Shareholders https://www.biopharmawatch.com/news/DAVI/davion-healthcare-acquisition-humaskan-medical-technology BiopharmaWatch en 2026-10-26T11:30:00.000Z Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP https://www.biopharmawatch.com/news/BWAY/brainsway-expands-insurance-coverage-deep-tms-ocd BiopharmaWatch en 2026-10-26T11:30:00.000Z BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives https://www.biopharmawatch.com/news/MDCX/medicus-pharma-regains-nasdaq-compliance BiopharmaWatch en 2026-10-26T11:30:00.000Z Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-first-patient-dosed-xtx501-trial BiopharmaWatch en 2026-10-26T11:30:00.000Z Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC https://www.biopharmawatch.com/news/IMRX/immuneering-phase-3-mapkeeper-301-trial-esmo-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 https://www.biopharmawatch.com/news/MGNX/macrogenics-positive-phase-2-linnet-results-lorigerlimab BiopharmaWatch en 2026-10-26T11:06:00.000Z MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-neurotechnology-ai-devices-southeast-asia BiopharmaWatch en 2026-10-26T11:00:00.000Z Healthcare Triangle Enters Neurotechnology AI Devices and Solutions for Southeast Asia https://www.biopharmawatch.com/news/CANF/can-fite-phase-iia-namodenoson-esmo-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 https://www.biopharmawatch.com/news/CANF/can-fite-phase-iia-namodenoson-pancreatic-cancer-esmo-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026 https://www.biopharmawatch.com/news/CGEN/compugen-release-q3-2026-results-november-9 BiopharmaWatch en 2026-10-26T11:00:00.000Z Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/CGEN/compugen-q3-2026-results-release BiopharmaWatch en 2026-10-26T11:00:00.000Z Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/REGN/regeneron-barda-agreement-inmazeb-ebola-treatment BiopharmaWatch en 2026-10-26T11:00:00.000Z Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness https://www.biopharmawatch.com/news/REGN/regeneron-barda-agreement-ebola-treatment-inmazeb BiopharmaWatch en 2026-10-26T11:00:00.000Z Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness https://www.biopharmawatch.com/news/NTRA/natera-asn-kidney-week-2026-genetic-testing-renasight BiopharmaWatch en 2026-10-26T11:00:00.000Z Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™ https://www.biopharmawatch.com/news/ENTA/enanta-resolve-phase-2b-3-zelicapavir-rsv BiopharmaWatch en 2026-10-26T11:00:00.000Z Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) https://www.biopharmawatch.com/news/IMNM/immunome-varegacestat-esmo-2026-data BiopharmaWatch en 2026-10-26T11:00:00.000Z Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 https://www.biopharmawatch.com/news/GMAB/genmab-phase-2-data-petosemtamab-pembrolizumab-hnscc BiopharmaWatch en 2026-10-26T11:00:00.000Z Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-lupus-nephritis-asn-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 https://www.biopharmawatch.com/news/PLUR/pluri-zeo-partner-us-manufacturing-regenerative-medicine BiopharmaWatch en 2026-10-26T11:00:00.000Z Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-orka-001-results-everlast-b-trial BiopharmaWatch en 2026-10-26T11:00:00.000Z Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis https://www.biopharmawatch.com/news/ELDN/eledon-phase-2-bestow-trial-data-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting https://www.biopharmawatch.com/news/HROW/harrow-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-26T11:00:00.000Z Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-26T11:00:00.000Z Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/IOVA/iovance-lifileucel-esmo-2026-data BiopharmaWatch en 2026-10-26T11:00:00.000Z Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026 https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q3-2026-results-call BiopharmaWatch en 2026-10-26T11:00:00.000Z Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/SNDX/syndax-announces-q3-2026-results-conference-call BiopharmaWatch en 2026-10-26T11:00:00.000Z Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 https://www.biopharmawatch.com/news/PLX/protalix-bio-present-stifel-2026-healthcare-conference BiopharmaWatch en 2026-10-26T10:50:00.000Z Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-eik1001-esmo-2026 BiopharmaWatch en 2026-10-26T10:00:00.000Z Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/MDLN/medline-10-years-partnership-wrap-responsible-manufacturing BiopharmaWatch en 2026-10-26T09:00:00.000Z Medline Celebrates 10 Years of Partnership with WRAP, Advancing Responsible Manufacturing https://www.biopharmawatch.com/news/BNTX/biontech-dualitybio-dynasty-breast02-trial-results BiopharmaWatch en 2026-10-26T09:00:00.000Z BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer https://www.biopharmawatch.com/news/HCM/hutchmed-sanovo-phase-iii-orpathys-tagrisso-lung-cancer BiopharmaWatch en 2026-10-26T08:30:00.000Z HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 https://www.biopharmawatch.com/news/YI/111-inc-appoints-independent-advisors-special-committee BiopharmaWatch en 2026-10-26T08:00:00.000Z 111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-fda-litigation-update BiopharmaWatch en 2026-10-26T08:00:00.000Z Phathom Pharmaceuticals Provides Update on FDA Litigation https://www.biopharmawatch.com/news/BMY/iza-bren-doubles-pfs-egfr-nsclc-study BiopharmaWatch en 2026-10-26T07:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study https://www.biopharmawatch.com/news/BMY/iza-bren-doubles-pfs-nsclc-study BiopharmaWatch en 2026-10-26T07:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-26 BiopharmaWatch en 2026-10-26T07:15:24.500Z IGALMI PDUFA for Agitation: Biotech Catalysts Oct 26, 2026 https://www.biopharmawatch.com/news/DRIO/dario-expands-contract-grocery-retailer-womens-health BiopharmaWatch en 2026-10-26T00:00:00.000Z Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program https://www.biopharmawatch.com/news/HCM/hutchmed-saffron-phase-iii-trial-results BiopharmaWatch en 2026-10-26T00:00:00.000Z HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-host-conference-call-report-week-16-data-orka BiopharmaWatch en 2026-10-25T16:00:00.000Z Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 https://www.biopharmawatch.com/news/SMMT/ivonescimab-chemotherapy-advanced-biliary-tract-cancer BiopharmaWatch en 2026-10-25T15:52:00.000Z Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China